| Ytd | -79.33% | |
| 1y | -95.02% |
| Open | 1.41 | Prev Close | 1.39 | Low | 1.35 | High | 1.42 | Mkt Cap | 191.92K |
| Vol | 18.50K | Avg Vol | 308.79K | EPS | -20.63 | P/E | -0.07 | Forward P/E | -1.69 |
| Beta | 0.68 | Short Ratio | 0.43 | Inst. Own | 9.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 2.37 | 200-d Avg | 5.09 | 1yr Est | 33.00 |
PPBT News
Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clini
Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing
https://www.sec.gov/Archives/edgar/data/1614744/000121390026059665/ea0291624-f3_purple.htm
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.09) per share which beat the analyst c
IM1240 is a conditionally activated, capped-CD3 × 5T4 × NKG2A tri-specific designed to direct tumor-
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clini
Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd
Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corpor
ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (
Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT - Get Free Report) saw a large increase in short int
Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT) shares are going to reverse split on the morning of
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique mul
Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milest
Achieved commercially viable yield for IM1240, positioning the program competitively for future deve
REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Com
REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Co
REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Com
Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager
REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Com
REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Com
Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strat
U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a prov
REHOVOT, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Co
Completed successful clinical trials for CM24 and NT21 9 oncology assets , demonstrating clinical be
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in com
On Thursday, 1076 companies hit new 52-week lows.
On Thursday, 588 stocks hit new 52-week lows.